Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099947 | 0.84 | KMT2A (0.48) | HSD17B10RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL11369484 | 0.84 | HSD17B10 (0.56) | HSD17B10KAT2BKMT2AALDH1A1 | |
| SCHEMBL5099886 | 0.83 | KAT2B (0.45) | KAT2BPOLBCHRM2HTTALDH1A1 | |
| SCHEMBL5099870 | 0.83 | KAT2B (0.51) | KAT2BPOLBKMT2ACHRM2MEN1 | |
| SCHEMBL5106327 | 0.82 | PTGDR2 (0.43) | HSD17B10KAT2BRAB9ANPC1POLB | |
| SCHEMBL5099412 | 0.81 | TSHR (0.42) | HSD17B10KAT2BNPC1POLBKMT2A | |
| SCHEMBL10860961 | 0.81 | HSD17B10 (0.53) | HSD17B10RAB9ANPC1KMT2AMAPT | |
| SCHEMBL5106227 | 0.81 | KAT2B (0.54) | KAT2BPOLBKMT2ACHRM2MEN1 | |
| SCHEMBL5105804 | 0.80 | POLB (0.57) | KAT2BPOLBKMT2ACHRM2MEN1 | |
| SCHEMBL5093313 | 0.80 | MAPT (0.52) | HSD17B10RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449477-B2 | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070037796-A1 | e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms | ELI LILLY AND COMPANY | 2007-02-15 | — | — | US | disclosed |
| EP-1689719-A1 | 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B) | ELI LILLY AND COMPANY (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054202-A1 | 7-PHENYL-ISOQUINOLINE-5-SULFONYLAMINO DERIVATIVES AS INHIBITORS OF AKT (PROTEINKINASE B) | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037796-A1 | e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms | POLI, HRAS, CHUK | HSD17B10 2947/4885KAT2B 2748/4885RAB9A 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.